Neuphoria Therapeutics
NEUP
19 hedge funds and large institutions have $7.15M invested in Neuphoria Therapeutics in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 7 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
26% more capital invested
Capital invested by funds: $5.69M → $7.15M (+$1.47M)
5.35% more ownership
Funds ownership: 27.26% → 32.61% (+5.3%)
10% less funds holding
Funds holding: 21 → 19 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$601K |
| 2 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$324K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
| 4 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$89.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$81.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$194K |
| 2 |
SC
Shay Capital
New York
|
-$76.3K |
| 3 |
Jane Street
New York
|
-$64.4K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$57.2K |
| 5 |
PAP
Persistent Asset Partners
Hong Kong
|
-$52K |
NEUP Hedge Fund Activity: Q1 2026 in Review
19 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q1 2026, worth a combined $7.15M — up 26% from $5.69M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NEUP and 6 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $601K. The largest seller was Diadema Partners, exiting entirely with an estimated $194K sold.
- 19 institutional investors held Neuphoria Therapeutics (NEUP) as of Q1 2026, down from 21 in Q4 2025.
- Funds reported $7.15M of Neuphoria Therapeutics stock for Q1 2026, up 26% quarter-over-quarter.
- 6 funds opened new Neuphoria Therapeutics positions in Q1 2026 and 7 closed out, a net change of -1 holder.
- The largest Neuphoria Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $601K added.
- The largest Neuphoria Therapeutics seller in Q1 2026 was Diadema Partners, an estimated $194K sold.
Based on aggregated 13F filings for Q1 2026.